INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in The Chemours Company to Contact Law Firm
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in The Chemours Company to Contact Law Firm
PR Newswire
NEW YORK, Oct. 20, 2026
- The Chemours Company (NYSE: CC) shareholders should email fletcher@fmoorelaw.com
NEW YORK, Oct. 20, 2026 /PRNewswire/ --
What is the Investigation About?
On August 4, 2026, after the market closed, Chemours announced second-quarter results and reduced its full-year adjusted EBITDA guidance from $800 million–$900 million to $775 million–$825 million. During the earnings call the following morning, management disclosed that customers had accumulated excess inventory of Opteon refrigerants, leaving the aftermarket channel oversupplied heading into 2026.
Following this news, the price of Chemours stock fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.
Management identified approximately $65 million in aftermarket sales that it indicated should have been allocated to the current year. Following the disclosures, UBS downgraded Chemours from "Buy" to "Neutral" and reduced its price target by 37.9%, citing analysis indicating that Chemours had oversold products in 2025 and likely early 2026. Morgan Stanley and J.P. Morgan also lowered their price targets.
If you own The Chemours Company (NYSE: CC) securities, please contact Fletcher Moore at fletcher@fmoorelaw.com.
You may be able to seek monetary damages, corporate governance reforms, reimbursement to the company, and a court approved incentive award at no cost to you whatsoever. All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
MOORE LAW PLLC
30 Wall Street, 8th Floor
New York, NY 10005
fletcher@fmoorelaw.com
www.fmoorelaw.com
SOURCE Moore Law PLLC
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
5 Stocks to Buy Trading at Big Discounts
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
United States